Home / Knowledge hub /
A bridge between design and delivery: Exploring sterile fill finish integration for injectable product success
November 14, 2025
The global sterile injectable contract manufacturing market is experiencing rapid growth, driven by increasing demand for advanced biologics, glucagon-like peptide-1 (GLP-1) therapies and other injectables. These products pair drugs with delivery devices to support patient-centric care, but their manufacturing presents unique challenges. Programs often require specialized environments, such as cold-chain storage and low-volume fills, and must be compatible with complex delivery systems.
To navigate these challenges, many companies partner with multiple vendors for different stages of the manufacturing process, which can introduce risks such as contamination, delays and regulatory complications. A fragmented approach can lead to a lack of alignment, making it difficult to maintain control and meet project timelines.
To mitigate these risks, integrated contract development and manufacturing organization (CDMO) models are becoming essential. Kindeva’s world-class Bridgeton facility in Missouri offers a unified, end-to-end sterile fill finish platform designed to eliminate these risks. The facility features over 155,000 square feet of current Good Manufacturing Practice (cGMP)-compliant aseptic manufacturing space, offering a range of integrated services, including fill finish, device assembly and packaging, all under one roof. This integrated model helps reduce handoffs and shorten timelines.
Kindeva brings together quality, scalability and speed under one roof to meet the evolving demands of sterile injectable. The specialized capabilities include:
- Integrated services, including fill finish, device assembly and packaging, all occur under one roof, reducing handoffs and timelines.
- Scalable manufacturing, supporting growth throughout the product lifecycle, from clinical trial materials to commercial-scale production.
- Annex 1-aligned design, with the facility engineered to comply with the latest Annex 1 requirements, prioritizing contamination control with isolator technology.
- Controlled substance expertise, with approval for Drug Enforcement Administration (DEA) Schedules III and IV, with capabilities extending to Schedule II.
Download the application note to discover how Kindeva’s Bridgeton facility simplifies complex manufacturing. Download here
To learn more about how Bridgeton acts as a strategic bridge between product development and patient-ready delivery, download our eBook.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Q&A: Navigating tech transfer and production pitfalls
Successful tech transfer alignment requires robust risk management and precise operational planning. When communication gaps or unforeseen supply chain hurdles emerge, project timelines and product quality are often the first to be affected. In this Q&A, we explore the common pitfalls of pharmaceutical tech transfers, including how to protect critical milestones without compromising safety and […]
Learn More
Webinar | Beyond the filling suite: How modular facility design supports sterile manufacturing success
Sterile manufacturing requirements are fast evolving, which means that many organizations are reassessing whether their legacy facilities can support future operational and regulatory demands. In this webinar, John Wichelt, Vice President and General Manager at Kindeva’s Bridgeton site, explores what a modern sterile fill finish facility needs to look like in this new era. Drawing […]
Learn More
What does Annex 1 mean for sterile drug product manufacturing?
Annex 1 compliance remains a key priority for companies working in sterile drug product manufacturing. But recognizing how fundamentally expectations around sterility assurance have changed may be the most significant challenge companies face. Revisions to the EU GMP Annex 1 requirements now move beyond individual compliance activities and place greater emphasis on how contamination risks […]
Learn More
Explore our world-class sterile injectable facility in Bridgeton, Missouri | Video tour
Spanning over 155,000 sq. ft. of dedicated aseptic operations space, our Bridgeton, MO facility brings together leading expertise, advanced automation and Annex 1-compliant isolator technology to help support growing global demand for sterile injectables. Designed to deliver excellence from floor to ceiling, Bridgeton seamlessly connects development and delivery through flexible fill finish infrastructure that helps […]
Learn More
PharmaSource podcast with Tommy Schornak
Today’s pharmaceutical companies must manage tight timelines and high demand for products, as well as shifting regulatory requirements and an increasingly complex global supply chain. How can contract development and manufacturing organizations (CDMOs) rise to this challenge and provide the support they need? In this podcast with PharmaSource, Tommy Shornak, Senior Vice President, Sterile Injectables, […]
Learn More
The bridge to uncompromising fill finish precision
Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]
Learn More
The bridge to the future of sterile injectables
Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.